This medicine represents the single greatest therapeutic advancement in the history of CF, offering a treatment for the underlying cause of the disease that could eventually benefit more than 90 percent of people with CF.
Legislation Would Increase Patient and Expert Participation in FDA Review of Rare Disease Treatments
New Effort Will Search for Potential Therapies Targeting the Most Common Mutation of Cystic Fibrosis
CF Foundation's $1 Million Investment Helped Drug Known as Cayston® Become a Reality
Galapagos and Cystic Fibrosis Foundation Therapeutics Sign €1.3 million* Agreement
Cystic Fibrosis Foundation Therapeutics to Provide Alnylam with $1.5 Million in Funding for Discovery Efforts